Oral cancer is both prevalent and fatal, with late diagnosis needing aggressive treatments that have a slimmer chance of success. Identifying oral cancer early is imperative to beating it.
The biomarkers associated with oral cancer risk can be detected by the BeVigilant™ OraFusion™ System from Vigilant Biosciences®. The innovative technology provides simple and accurate assessments of the patient’s risk level – low, moderate or high risk – generating a ‘Monitor’ or ‘Investigate Further’ prompt.
Supporting the level of early intervention that can successfully treat cancer, the BeVigilant™ OraFusion™ System is easy to set-up and use, with results available in 15 minutes or less. This fast turnaround allows practitioners and patients to discuss the results and what to do next within the same appointment.
Being able to do a quick test can better confirm the risk of a patient developing oral cancer. With the BeVigilant™ OraFusion™ System, oral cancer can be detected early.
For more information, visit www.vigilantbiosciences.com or email info@vigilantbiosciences.com
